Shattuck Labs (STTK)
Market Price (5/20/2026): $5.8 | Market Cap: $651.0 MilSector: Health Care | Industry: Biotechnology
Shattuck Labs (STTK)
Market Price (5/20/2026): $5.8Market Cap: $651.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -72% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -53 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5266% Expensive valuation multiplesP/SPrice/Sales ratio is 650x Stock price has recently run up significantly6M Rtn6 month market price return is 188%, 12M Rtn12 month market price return is 451% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -78% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 769% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4127%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4127% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 71% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% High stock price volatilityVol 12M is 101% Key risksSTTK key risks include [1] the unpredictable outcome of its clinical trials and subsequent regulatory approvals and [2] future liquidity needs, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -72% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -53 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5266% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 650x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 188%, 12M Rtn12 month market price return is 451% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -78% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 769% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4127%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4127% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 71% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% |
| High stock price volatilityVol 12M is 101% |
| Key risksSTTK key risks include [1] the unpredictable outcome of its clinical trials and subsequent regulatory approvals and [2] future liquidity needs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Advancement of Lead Clinical Asset SL-325 with Expected Key Data Readouts: Shattuck Labs completed enrollment in all single and multiple-ascending dose cohorts for its Phase 1 clinical trial of SL-325, a DR3 blocking antibody for inflammatory and immune-mediated diseases. Full Phase 1 data are anticipated in Q2 2026, with plans to initiate a Phase 2 trial in Crohn's disease in Q3 2026, subject to positive data and regulatory alignment.
2. Stronger Financial Position and Extended Cash Runway: The company reported a narrowed operating loss to less than $13.4 million for Q4 2025, an improvement from $19.6 million in the same period of 2024, and a Q4 2025 net loss of $0.12 per share, which was better than the average analyst estimate of $0.13. As of March 31, 2026, cash and short-term investments increased to $90.4 million, up from $60.9 million a year earlier. This capital, including potential proceeds from outstanding warrants, is expected to fund operations into 2029.
Show more
Stock Movement Drivers
Fundamental Drivers
The 49.6% change in STTK stock from 1/31/2026 to 5/19/2026 was primarily driven by a 132.6% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.87 | 5.79 | 49.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 0.0% |
| P/S Multiple | 279.4 | 649.8 | 132.6% |
| Shares Outstanding (Mil) | 72 | 112 | -35.7% |
| Cumulative Contribution | 49.6% |
Market Drivers
1/31/2026 to 5/19/2026| Return | Correlation | |
|---|---|---|
| STTK | 49.6% | |
| Market (SPY) | 6.3% | 19.6% |
| Sector (XLV) | -4.4% | -5.1% |
Fundamental Drivers
The 201.6% change in STTK stock from 10/31/2025 to 5/19/2026 was primarily driven by a 1888.8% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.92 | 5.79 | 201.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 1 | -66.6% |
| P/S Multiple | 32.7 | 649.8 | 1888.8% |
| Shares Outstanding (Mil) | 51 | 112 | -54.6% |
| Cumulative Contribution | 201.6% |
Market Drivers
10/31/2025 to 5/19/2026| Return | Correlation | |
|---|---|---|
| STTK | 201.6% | |
| Market (SPY) | 8.2% | 17.8% |
| Sector (XLV) | 3.0% | -0.3% |
Fundamental Drivers
The 485.4% change in STTK stock from 4/30/2025 to 5/19/2026 was primarily driven by a 7293.8% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.99 | 5.79 | 485.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 1 | -82.5% |
| P/S Multiple | 8.8 | 649.8 | 7293.8% |
| Shares Outstanding (Mil) | 51 | 112 | -54.7% |
| Cumulative Contribution | 485.4% |
Market Drivers
4/30/2025 to 5/19/2026| Return | Correlation | |
|---|---|---|
| STTK | 485.4% | |
| Market (SPY) | 33.8% | 20.1% |
| Sector (XLV) | 6.7% | 15.3% |
Fundamental Drivers
The 93.0% change in STTK stock from 4/30/2023 to 5/19/2026 was primarily driven by a 233.2% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.00 | 5.79 | 93.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 53.4% |
| P/S Multiple | 195.0 | 649.8 | 233.2% |
| Shares Outstanding (Mil) | 42 | 112 | -62.2% |
| Cumulative Contribution | 93.0% |
Market Drivers
4/30/2023 to 5/19/2026| Return | Correlation | |
|---|---|---|
| STTK | 93.0% | |
| Market (SPY) | 83.3% | 18.5% |
| Sector (XLV) | 16.0% | 17.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| STTK Return | -84% | -73% | 210% | -83% | 202% | 64% | -89% |
| Peers Return | 36% | 21% | 2% | 8% | 26% | 2% | 132% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| STTK Win Rate | 25% | 17% | 58% | 42% | 58% | 80% | |
| Peers Win Rate | 62% | 62% | 43% | 47% | 60% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| STTK Max Drawdown | -84% | -78% | -71% | -91% | -62% | -26% | |
| Peers Max Drawdown | -16% | -18% | -23% | -21% | -22% | -14% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MRK, ABBV, PFE, LLY, JNJ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/19/2026 (YTD)
How Low Can It Go
| Event | STTK | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.8% | -18.8% |
| % Gain to Breakeven | 71.9% | 23.1% |
| Time to Breakeven | 3 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -18.9% | -7.8% |
| % Gain to Breakeven | 23.3% | 8.5% |
| Time to Breakeven | 29 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.5% | -9.5% |
| % Gain to Breakeven | 90.5% | 10.5% |
| Time to Breakeven | 71 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.4% | -6.7% |
| % Gain to Breakeven | 79.8% | 7.1% |
| Time to Breakeven | 210 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -70.9% | -24.5% |
| % Gain to Breakeven | 243.2% | 32.4% |
| Time to Breakeven | 438 days | 427 days |
In The Past
Shattuck Labs's stock fell -41.8% during the 2025 US Tariff Shock. Such a loss loss requires a 71.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | STTK | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.8% | -18.8% |
| % Gain to Breakeven | 71.9% | 23.1% |
| Time to Breakeven | 3 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.5% | -9.5% |
| % Gain to Breakeven | 90.5% | 10.5% |
| Time to Breakeven | 71 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.4% | -6.7% |
| % Gain to Breakeven | 79.8% | 7.1% |
| Time to Breakeven | 210 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -70.9% | -24.5% |
| % Gain to Breakeven | 243.2% | 32.4% |
| Time to Breakeven | 438 days | 427 days |
In The Past
Shattuck Labs's stock fell -41.8% during the 2025 US Tariff Shock. Such a loss loss requires a 71.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Shattuck Labs (STTK)
AI Analysis | Feedback
Here are a few analogies for Shattuck Labs:
A startup Amgen for cancer and autoimmune drug discovery.
Like a small, independent R&D lab for Pfizer or Merck, but focused on experimental drugs for cancer and autoimmune diseases.
AI Analysis | Feedback
```html- SL-172154: A therapeutic product candidate in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
- SL-279252: A therapeutic product candidate in Phase 1 clinical trial for patients with advanced solid tumors and lymphoma.
AI Analysis | Feedback
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and autoimmune diseases. As described, their lead product candidates are currently in Phase 1 clinical trials. This means the company is in the research and development phase and has not yet commercialized any products or services.
Therefore, Shattuck Labs does not have major customers in the traditional sense of companies or individuals purchasing their products or services.
AI Analysis | Feedback
null
AI Analysis | Feedback
Taylor H. Schreiber, MD, PhD Chief Executive Officer, Co-founder, and Director
Dr. Schreiber co-founded Shattuck Labs in 2016 and served as Chief Scientific Officer before his appointment as CEO in January 2020. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc., where he co-invented significant elements of their ImPACT and ComPACT technology platforms. He also co-invented TNFRSF25 agonist technology developed by Pelican Therapeutics, Inc., where he served as Chairman of the Scientific Advisory Board. Pelican Therapeutics was sold in 2017.
Andrew R. Neill Chief Financial Officer
Mr. Neill has served as Chief Financial Officer of Shattuck Labs since March 2021, having joined the company in 2017. He previously served as Vice President of Finance and Corporate Strategy, and Vice President of Corporate Development and Strategy. Prior to joining Shattuck, Mr. Neill was the co-founder of Lumos Pharma, a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. He played a key role in Shattuck's Series B and B-1 financings and initial public offering.
Lini Pandite, MD, MBA Chief Medical Officer
Dr. Pandite joined Shattuck Labs in July 2017 as Chief Medical Officer. She brings over 25 years of academic, medical, and pharmaceutical experience with broad expertise in oncology drug development, spanning from early-to-late phase development through registration and commercialization.
Suresh de Silva, PhD Chief Scientific Officer
Dr. de Silva has served as Chief Scientific Officer since January 2023. He joined Shattuck in 2017 and is one of the scientific co-inventors of the ARC technology platform. He previously served as Vice President of Product Development and Executive Director of Research and Development. Prior to Shattuck, he was the Director of Research and Development at Heat Biologics, Inc., where he co-developed the ComPact cell-based vaccine platform.
Casi DeYoung Chief Business Officer
Ms. DeYoung has served as Chief Business Officer since December 2019. From June 2018 to December 2019, she served as Vice President and Chief Operating Officer for ImmuneSensor Therapeutics, an immunotherapy-focused biotechnology company, where she was responsible for corporate strategy, start-up operations, intellectual property, oversight of the company's first IND filing, and the initiation of a first-in-human Phase I clinical trial.
AI Analysis | Feedback
The key risks for Shattuck Labs (STTK), a clinical-stage biotechnology company, primarily revolve around the inherent uncertainties of drug development and commercialization in the highly regulated and competitive biotechnology sector.
-
Clinical Trial Failure: Shattuck Labs' valuation and future prospects are heavily dependent on the successful outcome of its ongoing clinical trials, particularly for its lead product candidate, SL-325. There is no guarantee that preliminary data for SL-325, currently in Phase 1 for inflammatory bowel diseases (IBD), will be positive or viewed favorably by the market. The company has previously discontinued its SL-172154 oncology program due to "modest improvement" in overall survival, highlighting the tangible risk and impact of clinical trial failures, which can lead to significant financial losses and strategic shifts. Biotechnology development is characterized by high attrition rates and substantial development costs, making clinical success a paramount risk.
-
Regulatory Approval Risk: As with all biotechnology companies, Shattuck Labs faces significant inherent risks associated with obtaining regulatory approvals for its drug candidates. The U.S. Food and Drug Administration (FDA) approval process is complex, lengthy, and never guaranteed, even with positive clinical data. Failure to comply with stringent regulatory requirements can result in severe penalties, delaying or preventing market access for potential therapies.
-
Lack of Profitability and Dependence on Future Funding: Shattuck Labs is currently a clinical-stage company with no product revenue, operating with significant net losses and negative operating margins. While the company has extended its cash runway, anticipating sufficient capital into 2029, this projection is contingent upon the full exercise of outstanding common stock warrants. The biotechnology industry often faces challenges in raising capital, particularly in an uncertain economic landscape, making sustained profitability and access to future funding critical risks.
AI Analysis | Feedback
nullAI Analysis | Feedback
Shattuck Labs (STTK) was developing therapeutics for several cancer indications. While their lead product candidates, SL-172154 and SL-279252, were initially aimed at these markets, Shattuck Labs has since discontinued their clinical development for these specific oncology programs.
Here are the addressable market sizes for the indications that Shattuck Labs' main products were initially targeting:
SL-172154 (Discontinued Oncology Program)
SL-172154 was in Phase 1 clinical trials for the treatment of ovarian, fallopian tube, and peritoneal cancers. However, Shattuck Labs discontinued the SL-172154 clinical program in October 2024 due to modest improvements in median overall survival compared to benchmarks, and shifted focus to other programs.
- Ovarian Cancer: The global ovarian cancer market size was valued at approximately USD 2.5 billion in 2025 and is projected to reach USD 5.8 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 9.21% from 2026 to 2034. North America is a leading region in this market.
- Fallopian Tube Cancer: The global fallopian tube cancer treatment market size was valued at USD 1.80 billion in 2025 and is expected to reach USD 3.35 billion by 2033, growing at a CAGR of 8.10%. North America held the largest revenue share in this market in 2025. The global fallopian tube cancer therapeutics market size was also calculated at USD 1.93 billion in 2025 and is predicted to increase to approximately USD 5.41 billion by 2035, expanding at a CAGR of 10.86% from 2026 to 2035.
- Peritoneal Cancer: Market sizes for primary peritoneal cancer are often integrated with those of ovarian and fallopian tube cancers due to their clinical similarities and shared treatment approaches.
SL-279252 (Discontinued Oncology Program)
SL-279252 was in Phase 1 clinical trials for advanced solid tumors and lymphoma. Shattuck Labs discontinued clinical development of SL-279252 in February 2023 because it did not observe an overall response rate necessary to justify continued development.
- Advanced Solid Tumors: The global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032, with a CAGR of 20.00% during the forecast period of 2025 to 2032. North America dominates the solid tumors market. Another source indicates the global solid tumor therapeutics market size reached USD 223.65 billion in 2026 and is forecast to reach USD 326.82 billion by 2031.
- Lymphoma: The global lymphoma treatment market size was valued at USD 8.3 billion in 2024 and is expected to reach USD 18.3 billion by 2034, growing at a CAGR of 8.4% from 2025 to 2034. The U.S. lymphoma treatment market was valued at USD 2.9 billion in 2023 and is projected to reach USD 6.8 billion by 2034. North America held a dominant share of approximately 49% in the global lymphoma treatment market in 2024.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Shattuck Labs (STTK) over the next 2-3 years:
- Successful Clinical Development and Regulatory Progress of SL-325: Shattuck Labs has shifted its primary focus to SL-325, a Death Receptor 3 (DR3) antagonist antibody, for the treatment of inflammatory bowel disease (IBD) and other inflammatory conditions. The company anticipated filing an Investigational New Drug (IND) application for SL-325 and initiating a Phase 1 clinical trial in the third quarter of 2025. Positive data from this ongoing Phase 1 trial and subsequent clinical development stages would be a key driver for future revenue, potentially leading to regulatory approvals and market entry.
- Strategic Partnerships and Licensing Agreements for SL-325: As a clinical-stage biotechnology company, a significant driver of future revenue growth could come from securing strategic collaborations or licensing agreements for SL-325. Successful early-stage clinical data for SL-325 could attract larger pharmaceutical partners, potentially resulting in upfront payments, milestone payments, and future royalties, which could contribute to revenue within the specified timeframe.
- Expansion of the DR3 Blocking Antibody Pipeline: Beyond SL-325, Shattuck Labs is also working on nominating additional lead DR3 bispecific development candidates. The successful advancement and diversification of its DR3 blocking antibody pipeline could create multiple future product opportunities and revenue streams in the long term, building upon the initial development of SL-325.
AI Analysis | Feedback
Share Repurchases
No information available regarding share repurchases or authorized future share repurchases over the last 3-5 years.
Share Issuance
- Shattuck Labs sold shares of its common stock under an at-the-market offering facility, generating aggregate gross proceeds of $21.4 million in the first quarter of 2026.
- The company's number of shares outstanding increased by 37.09% in one year.
- As of February 28, 2026, cash, cash equivalents, and short-term investments totaled approximately $94.5 million, which included the $21.4 million in gross proceeds from at-the-market stock sales.
Inbound Investments
- As a result of at-the-market stock sales in the first quarter of 2026, accounts advised by T. Rowe Price Investment Management, Inc. reported beneficial ownership exceeding 10% of Shattuck Labs' outstanding common stock.
Capital Expenditures
- Shattuck Labs' capital expenditures in the last 12 months were -$71,000.
- The company reported $0 in capital expenditures in the fourth quarter of 2025.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to STTK.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 164.00 |
| Mkt Cap | 330.4 |
| Rev LTM | 64,541 |
| Op Inc LTM | 18,176 |
| FCF LTM | 12,242 |
| FCF 3Y Avg | 11,334 |
| CFO LTM | 19,185 |
| CFO 3Y Avg | 14,679 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.4% |
| Rev Chg 3Y Avg | 4.4% |
| Rev Chg Q | 9.9% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Inc Chg LTM | 25.2% |
| Op Inc Chg 3Y Avg | 43.2% |
| Op Mgn LTM | 25.6% |
| Op Mgn 3Y Avg | 22.7% |
| QoQ Delta Op Mgn LTM | -0.6% |
| CFO/Rev LTM | 25.5% |
| CFO/Rev 3Y Avg | 22.7% |
| FCF/Rev LTM | 16.5% |
| FCF/Rev 3Y Avg | 17.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 330.4 |
| P/S | 5.9 |
| P/Op Inc | 19.8 |
| P/EBIT | 21.4 |
| P/E | 29.0 |
| P/CFO | 16.8 |
| Total Yield | 5.1% |
| Dividend Yield | 2.6% |
| FCF Yield 3Y Avg | 4.7% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.9% |
| 3M Rtn | -4.8% |
| 6M Rtn | 10.3% |
| 12M Rtn | 44.8% |
| 3Y Rtn | 61.1% |
| 1M Excs Rtn | -4.8% |
| 3M Excs Rtn | -11.9% |
| 6M Excs Rtn | 3.1% |
| 12M Excs Rtn | 22.3% |
| 3Y Excs Rtn | -19.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Drug discovery and development | 6 | 2 | 1 | 10 | |
| Total | 6 | 2 | 1 | 10 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Drug discovery and development | -81 | -92 | |||
| Total | -81 | -92 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Drug discovery and development | -75 | -87 | |||
| Total | -75 | -87 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Drug discovery and development | 299 | ||||
| Total | 299 |
Price Behavior
| Market Price | $5.79 | |
| Market Cap ($ Bil) | 0.6 | |
| First Trading Date | 10/09/2020 | |
| Distance from 52W High | -26.5% | |
| 50 Days | 200 Days | |
| DMA Price | $6.69 | $3.69 |
| DMA Trend | up | up |
| Distance from DMA | -13.4% | 56.8% |
| 3M | 1YR | |
| Volatility | 70.9% | 101.2% |
| Downside Capture | 56.75 | 48.37 |
| Upside Capture | 179.38 | 241.76 |
| Correlation (SPY) | 10.6% | 19.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.05 | 0.33 | 0.71 | 0.86 | 1.56 | 1.66 |
| Up Beta | 1.40 | 1.15 | 1.36 | 0.89 | 1.11 | 1.54 |
| Down Beta | -2.69 | -2.18 | -1.27 | 1.45 | 2.17 | 2.42 |
| Up Capture | 247% | 295% | 257% | 336% | 713% | 295% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 24 | 34 | 68 | 131 | 356 |
| Down Capture | 374% | -187% | -47% | -142% | 31% | 106% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 17 | 28 | 53 | 115 | 371 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STTK | |
|---|---|---|---|---|
| STTK | 481.5% | 100.9% | 2.20 | - |
| Sector ETF (XLV) | 12.7% | 14.7% | 0.60 | 12.4% |
| Equity (SPY) | 25.0% | 12.1% | 1.55 | 18.9% |
| Gold (GLD) | 40.0% | 26.8% | 1.23 | 11.4% |
| Commodities (DBC) | 49.4% | 18.5% | 2.03 | 2.9% |
| Real Estate (VNQ) | 9.7% | 13.4% | 0.45 | 14.4% |
| Bitcoin (BTCUSD) | -25.6% | 41.9% | -0.59 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STTK | |
|---|---|---|---|---|
| STTK | -25.6% | 117.2% | 0.23 | - |
| Sector ETF (XLV) | 5.6% | 14.6% | 0.20 | 17.2% |
| Equity (SPY) | 14.2% | 17.0% | 0.65 | 20.1% |
| Gold (GLD) | 19.3% | 18.0% | 0.87 | 2.9% |
| Commodities (DBC) | 11.0% | 19.4% | 0.45 | 2.0% |
| Real Estate (VNQ) | 4.0% | 18.8% | 0.11 | 18.2% |
| Bitcoin (BTCUSD) | 9.4% | 55.6% | 0.38 | 11.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STTK | |
|---|---|---|---|---|
| STTK | -10.5% | 114.5% | 0.30 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 15.1% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 18.6% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 2.5% |
| Commodities (DBC) | 8.4% | 17.9% | 0.38 | 1.7% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 16.6% |
| Bitcoin (BTCUSD) | 67.2% | 66.9% | 1.06 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | 7.8% | 24.3% | 35.7% |
| 5/1/2025 | -7.8% | -13.0% | -3.2% |
| 11/14/2024 | 12.3% | -9.0% | -6.6% |
| 11/9/2023 | -23.2% | -8.9% | 0.0% |
| 8/10/2023 | -2.3% | -5.9% | -1.4% |
| 5/9/2023 | -2.1% | -7.0% | 2.8% |
| 2/23/2023 | 0.4% | -9.5% | -33.3% |
| 11/8/2022 | -5.9% | 1.8% | 6.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 4 | 6 |
| # Negative | 7 | 10 | 8 |
| Median Positive | 4.4% | 11.5% | 6.0% |
| Median Negative | -5.9% | -7.9% | -9.0% |
| Max Positive | 12.3% | 24.3% | 35.7% |
| Max Negative | -28.6% | -34.5% | -50.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 5142026 | 7.01 | 2,032 | 14,244 | 569,619 | Form |
| 2 | Pandite, Arundathy N | Chief Medical Officer | Direct | Sell | 5142026 | 6.61 | 30,000 | 198,300 | 1,098,708 | Form |
| 3 | Orbimed, Advisors Llc | See Footnote | Buy | 9022025 | 0.87 | 6,306,127 | 5,471,826 | 4,559,855 | Form | |
| 4 | Ashiya, Mona | See Footnote | Buy | 9022025 | 0.87 | 6,306,127 | 5,471,826 | 4,559,855 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.